Skip to main content

RA Capital Management — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

453
Companies
$44.2B
Total invested
$123.1M
Avg. check
23
Industries
Biotechnology 19Health Care 15Therapeutics 10Medical 8Biopharma 5Pharmaceutical 5+17 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 453
Commons Clinic
July 2026

Commons Clinic is a multi-specialty clinic offering minimally-invasive surgical and conservative musculoskeletal care.

Health Care · Los Angeles$10.1M Venture - Series Unknown
Vesta Healthcare
July 2024

Vesta Healthcare is a technology and clinical services organization that offers virtual care services.

Elder Care · New York$10.0M Debt Financing
Day One Biopharmaceuticals
July 2024

Day One Biopharmaceuticals develops targeted therapies to treat people with life-threatening diseases.

Biopharma · South San Francisco$175.0M Post-IPO Equity
Claris Biotherapeutics
July 2026

Claris Biotherapeutics develops biologic therapies for corneal diseases and other disorders affecting the ocular surface.

Biopharma · Jersey City$118.0M Series B
Pahr Therapeutics
July 2025

Pahr Therapeutics is a clinical stage business, is to create innovative ways to treat pulmonary arterial hypertension.

Clinical Trials · Boston$14.0M Seed
Inozyme
July 2023

Inozyme is a biopharmaceutical company developing therapeutics for rare diseases, with a focus on bone health.

Biotechnology · Boston$60.0M Post-IPO Equity
Scribe Therapeutics
July 2026

Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR molecules.

Biotechnology · Alameda$7.5M Post-IPO Equity
Dyne Therapeutics
July 2026

Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.

Biotechnology · Cambridge$375.1M Post-IPO Equity
Achilles Therapeutics
July 2022

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.

Biotechnology · London$4.1M Grant
Freenome
July 2026

Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening.

Biotechnology · South San Francisco$240.0M Post-IPO Equity
LENZ Therapeutics
July 2024

LENZ Therapeutics operates as an organization engaged in the late-stage clinical development of pharmaceuticals for the eyes.

Health Care · Del Mar$30.0M Post-IPO Equity
Q32 Bio
July 2026

Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.

Biotechnology · Cambridge$200.0M Post-IPO Equity
Spero Therapeutics
July 2026

Spero Therapeutics develops therapeutics for treatment of gram-negative infections.

Biotechnology · Cambridge$105.0M Post-IPO Debt
Imara
July 2021

Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.

Biopharma · Cambridge$50.0M Post-IPO Equity
Ocelot Bio
July 2023

Ocelot Bio brings new treatment options to patients with severe liver disease.

Biotechnology · San Diego$3.0M Debt Financing
AM Batteries
July 2024

AM Batteries manufactures Li-ion batteries using solvent-free electrode manufacturing technology.

Electronics · Chelmsford$2.2M Grant
Septerna
July 2023

Septerna is a biotech firm unlocking diverse drug discovery potential in G protein-coupled receptors across various diseases.

Biotechnology · San Francisco$150.0M Series B
Element Biosciences
June 2026

Element Biosciences develops genomic sequencing and multiomics technologies used in drug discovery, and diagnostic applications.

Biotechnology · San DiegoSeries E
Tango Therapeutics
June 2026

Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.

Biotechnology · Cambridge$600.0M Post-IPO Equity
Mineralys Therapeutics
June 2026

Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.

Biopharma · Radnor$500.0M Post-IPO Debt
Celcuity
June 2026

Celcuity is a biotechnology company translating discoveries of new cancer sub-types into expanded therapeutic options for cancer patients.

Biotechnology · Hamel$500.0M Post-IPO Debt
SAB Biotherapeutics
March 2026

SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.

Biotechnology · Sioux Falls$85.0M Post Ipo Equity
Equillium
March 2026

Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.

Biopharma · La Jolla$35.0M Post Ipo Equity
Solid Biosciences
March 2026

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

Biotechnology · Charlestown$240.0M Post Ipo Equity

Where RA Capital Management invests

Biotechnology19
Health Care15
Therapeutics10
Medical8
Biopharma5
Pharmaceutical5

About RA Capital Management's portfolio

How many companies has RA Capital Management invested in?

RA Capital Management has invested in 453 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does RA Capital Management invest in?

RA Capital Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Biopharma. The firm invests across 23 different industry categories.

What is RA Capital Management's largest investment?

Among tracked funding rounds, Tango Therapeutics received $600.0M in a Post-IPO Equity round. RA Capital Management's total known invested capital is $44.2B.

What is the average investment size for RA Capital Management?

RA Capital Management's average investment size is $123.1M across its portfolio of 453 companies.

What are RA Capital Management's most recent investments?

Recent RA Capital Management portfolio additions include Commons Clinic, Vesta Healthcare, Day One Biopharmaceuticals, Claris Biotherapeutics, Pahr Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 453 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →